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Summary Red light (c. 630nm) is almost universally used in tumour phototherapy as it is the most
penetrating of the porphyrin excitation wavebands. However, measurements of tumour attenuation of light of
different wavelengths and of the excitation spectrum of haematoporphyrin derivative in vitro suggested that
green light might be more efficient than red in destroying thin tumours. Experimentally, we confirmed this for
tumours up to -1.2mm thick, a depth exceeding that of most carcinomas-in-situ. The superiority of green
light over red in terms of the illumination time required to produce equivalent depths of necrosis may extend
to greater depths (3-4mm) if the former is produced by an argon laser and the latter by an argon-pumped
dye laser.
The relation between depth of necrosis zn and light dose D is shown to be zn=ax 'n(D/lA) where 0A iS the
attenuation coefficient for light at wavelength A and 0A the threshold light dose for producing necrosis at that
wavelength. This logarithmic relationship suggests that it may be difficult to eradicate large tumours merely by
increasing the light dose, and indicates the need for other approaches.
Tumour phototherapy depends on the ability of
certain photosensitizing agents to localise in
tumours, so that exposure of the tumour to
sufficiently intense light of appropriate wavelength
causes its rapid necrosis. The photosensitiser most
widely used at present is "haematoporphyrin deriva-
tive" (HpD), a complex mixture of porphyrins
(Bonnett et al., 1980, 1981; Berenbaum et al., 1982).
HpD is excited at a number of discrete wavebands,
most intensely by violet light at 400-410nm (the
Soret band), and with much less (and decreasing)
intensity by bands at 500-505nm, 535-540nm,
565-575 nm and 620-635nm. Only the red
waveband (620-635nm) is used in tumour photo-
therapy as it has the greatest tissue penetration, an
essential requirement in treating most human
tumours, where light of adequate intensity may be
needed through 1 cm or more of tissue.
However, the use of red light has disadvantages.
First, generation of sufficiently intense red light
requires (at present) use of a dye laser pumped by
an ion laser, a costly and complicated arrangement.
Second, the red waveband is the least efficient
exciter of the porphyrin molecule.
Many human carcinomas do not demand use of
highly penetrating light. For example, carcinoma-in-
situ is usually well under 1 mm thick in most sites,
and many early invasive carcinomas are only a few
mm thick. The question therefore arises as to
whether illumination at wavebands other than the
red, with less penetration but more efficient
excitation, might be more suitable for such tumours.
Here, we compare the effectiveness of tumour
phototherapy at 405nm (in the Soret band),
514.5nm (the main output of the argon laser) and




This was either (a) a 4mgml-P solution in 0.5%
sodium hydrogen carbonate in PBS made from the
solid, provided by Dr T.J. Dougherty, of the
Roswell Park Memorial Institute or (b) the
commercially available 5mgml-1 solution
("Photofrin", Oncology Research and Development,
Inc., Cheektowaga, New York).
Excitation spectra in vitro
The fluorescence of HpD, lOpgml-' in'10% human
serum in PBS was measured at 690nm using the
fluorimeter constructed by the Physical Chemistry
group at the University of Amsterdam (Langelaar et
al., 1969) using a small path length to avoid
distortion of the spectrum by HpD absorption.
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Light attenuation and scattering
The tumour used for these measurements was the
BA 1112 rhabdomyosarcoma (Reinhold, 1966)
obtained from Prof. H.S. Reinhold, Radiobiological
Institute, TNO, the Netherlands. It was grown
subcutaneously in WAG-Rij rats and used 6 weeks
after implantation, when it was -4cm in diameter.
Measurements of attenuation and scattering were
made 2-3h after excision, using diffuse light from a
10cm integrating sphere, the interior of which was
illuminated through a laterally placed aperture by
light from a xenon arc used with a monochromator.
Tumour slices 0.7-1.4mm thick were held between
0.2 mm thick glass slides over a 1 cm aperture at the
top of the sphere. Diffuse transmittance through
them was measured by a photodiode (W34, AEG
Telefunken) and diffuse reflectance by a second
diode placed under an aperture in the bottom of the
sphere. Correction for reflection from the glass
surfaces was made using equations (4) and (5) of
Kottler (1960).
Reflection and transmission were analysed in
terms of absorption (A) and scattering (S)
coefficients using Kubelka-Munk theory (cf Kottler
(1960), equations (1OH12)), as follows: Space
irradiance Iz at tumour depth z is related to source
intensity Io by
Iz=(1-rSP)(1+rd)IOexp(-az) (1)
where rsp is the specular reflection coefficient of the
tumour (typically 0.04-0.05), rd the diffuse reflect-
ance from tumour thickness d and a is the
attenuation coefficient given by = A(A +2S)
(Ishimaru, 1978). With our data (Table I) and
assuming a "worst case" tumour depth of 8mm, rd
is - 0.09 at 630nm, 0.12 at 514.5nm and <0.08 at
405 nm. Thus, (1-rsp)(1 +rd) -1 at all wavelengths
used, and we accordingly used the approximation
(2)
Tumour necrosis
The PC6 plasma cell tumour, obtained originally
from the Chester Beatty Research Institute, was
passaged s.c. in BALB/c female mice, and used at
diameters up to 10-12mm and depths up to 6mm,
10-16 days after injection of 106 cells. HpD was
given in a fixed i.v. dose of 0.4mg 10g-' body
weight. Twenty-four hours later, the skin overlying
the tumour was shaved and depilated, mice were
anaesthetised and the tumours illuminated at
wavebands 405+18.6, 514.5+18.6 or 630+18.6nm
using a 900W xenon arc fitted with a f/3.4 grating
monochromator (Applied Photophysics Limited),
with a slit width of 8mm and a spectral band-pass
of 4.65nmmm- . Light intensity at the tumour
surface, measured with a thermopile (Model 14BT,
with indicator 154BT, Laser Instrumentation
Limited), varied in different experiments over the
ranges 90-107mWcm-2 at 405nm, 100-
108mWcm-2 at 514.5nm and 69-76mWcm-2 at
630nm, and light dose was varied by adjusting the
time of exposure. The depth of tumour necrosis was
measured 24h after illumination as described
previously (Berenbaum et al., 1982).
Results
Photophysical parameters
Table I shows relative excitation efficiencies for
HpD in 10% serum of light at 630, 514.5 and
405nm, and the values of A, S and a for tumour
(rhabdomyosarcoma). A and S at 630 and 514.5nm
were measured as described above. The value for A
at 405nm was calculated as follows. At 405 and
514.5nm, tissue absorption is dominated by its
blood content, but this has a negligible effect at
630nm (for oxygenated blood, A=4cm-1 at
630nm, 105cm-1 at 514.5nm and 2600cm-l at
405nm (Ishimaru, 1978; van Gemert & Hulsbergen
Henning, 1981)). Thus, the fractional blood volume
of the tumour may be estimated from the values for
A at 514.5 and 530nm (Table I) as (4.5-2.2)/105=
0.022, and its absorption coefficient at 405nm as
0.022x2600=57.2cm-'. The value of S at 405nm
was calculated using published data for wavelength
dependence of scattering (Anderson & Parrish,
Table I Relative excitation efficiencies (E) and absorption
(A), scattering (S) and attenuation (a) coefficients
Waveband Ea Ab Sb ac
(nm) (cm-') (cm-' (cm-')
630+ 18.6 1 2.2 5.0 5.2
514.5+ 18.6 2.37 4.5 7.4 9.3
405+18.6 19.7 57.2d 1.0oe 67.3
'Measured on HpD, 10igml-' in 10% human serum in
PBS. Arbitrary units, based on E=1 for 630+18.6nm,
taking into account a gaussian form for the wavebands,
with means at 630, 514.5 and 405nm and 50% values at
+ 18.6nm on either side of the mean.
bMeasured on the BA 112 tumour.
Cg= A(A+2S) (Ishimaru (1978), equations (10-6) and
(10-14).
dCalculation based on an estimated 2.2% (v/v) blood
content of tumour and data for blood from Ishimaru
(1978) and van Gemert & Hulsbergen Henning (1981) (see
text).
'Extrapolated value using the wavelength dependence of
dermal scattering (Anderson & Parrish, 1981) for scaling
(see text).
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1981), who found that values for S at 630, 514.5 and
405nm were in the ratios 6:9:14. These ratios, with
our experimentally determined values of 5 and
7.4cm-1 at the two longer wavelengths indicate a
value for S of c. II cm-' at 405nm.
The resulting attenuation coefficient at 405nm
(v=67.3cm- ', Table I) agrees with data obtained by
Eichler et al. (1977) for other tissues, which are in
the range 55-70cm-1. Our value of 5.2cm-t for a
for tumour at 630nm is close to the value of
6.3 cm- 1 found for a human lung carcinoma by
Svaasand et al. (1981). Further, measurements (not
presented here) on a rat urothelial tumour used
previously (Gijsbers et al., 1984) yielded results very
similar to those of Table I. The data in Table I may
therefore represent typical values for a range of
normal and neoplastic tissues.
Tumour necrosis
Figure 1 shows that there is a more or less linear
relation between depth of necrosis and the
logarithm of the light dose. Red light has the
steepest dose-effect curve (slope 0.20 when dose is
measured in natural logarithms) and the highest












the shallowest curve (slope - 0.023) and the lowest
threshold (about 0.8Jcm-2) and green light is
intermediate in both respects (slope 0.11 and
threshold 2.5Jcm-2). Whereas red light is the most
efficient of the three wavebands in causing tumour
necrosis at depths exceeding -1.2+0.5mm, green
light is more efficient at lesser depths. Violet light is
the most efficient only at depths less than - 0.2
+0.1mm.
Discussion
The relation between light dose and the extent of
tissue damage is of great importance in tumour
phototherapy. When tissues are illuminated in vivo,
light intensity falls more or less exponentially with
tissue depth (Eichler et al., 1977; Svaasand et al.,
1981). However, the rapid necrosis that ensues in
photosensitised tissues, due to formation of
chemically reactive singlet oxygen, does not.
Instead, there is a zone of completely necrotic tissue
and an abrupt transition to deeper tissue that
appears histologically undamaged (Berenbaum et
al., 1982, and Figure 2). This suggests that, for
L
5
Light dose (J cm-2)
10 50
Figure 1 Relation between light dose and depth of necrosis in the PC6 tumour at 630+ 18.6 nm (C1), 514.5
+ 18.6 nm (0) and 405+ 18.6 nm (0). The number of tumours used is indicated by each mean. Vertical bars
represent s.d. Linear regressions using the individual measurements are represented by the dashed curves: (---)
405+18.6nm; (-- 514+18.6nm; (--) 630+18.6nm.
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Figure 2 PC6 tumour 48 h after injection of HpD 40mgkg- and 24h after exposure of tumour to lOJcm-2
light at 630+ 18.6nm. The superficial aspect of the tumour is uppermost. Note the abrupt transition from
necrotic tumour above to apparently undamaged tumour below. (H&E, x 125).
production of necrosis, there is a threshold local
dose of singlet oxygen (the threshold varying with
the tissue), and that cells either die or survive,
according to whether the local dose exceeds or is
less than this. In this context, the "dose" of singlet
oxygen may be defined as the product of its local
concentration (102) and the time t over which that
concentration is maintained.
No information is available about singlet oxygen
levels or excitation behaviour in tissues during
phototherapy, so some reasonable assumptions are
necessary in analysing the results. First, as the
lifetime of singlet oxygen is negligible compared
with the time of exposure to light in phototherapy,
we may assume that the duration of exposure of
tissues to singlet oxygen is the same as that of their
exposure to light. Second, the relative excitation
efficiencies for HpD in tissues are assumed to be the
same as that in 10% serum. Third, as incident light
activates the porphyrin molecule but does not
influence the subsequent distribution of energy
between the paths leading, on the one hand, to
fluorescence and, on the other, to singlet oxygen
production (Dougherty et al., 1976), we assume that
the ratio of distribution of energy between these
two paths is fixed, and thus that relative
fluorescence excitation efficiencies at different
wavelengths and relative efficiencies for generating
singlet oxygen should be proportional to each
other. We therefore assume that the local dose
(102) t of singlet oxygen is proportional to relative
fluorescence excitation efficiency EA at wavelength A
(Table I) and to total light dose D (which is the
product of local space irradiance I and time t of
illumination), i.e.,
(102)t =kEAD (3)
Here k is a constant that depends on the level of
HpD in the tissue but, as HpD dose and the
interval between its administration and exposure to
light were fixed in these experiments, we may
assume a fixed HpD concentration in tumours at
the time of illumination.
From equation (3), threshold light doses OAI 6A2





That is, for light at different wavelengths, threshold
doses for producing tissue necrosis are inversely
proportional to their relative excitation efficiencies
for fluorescence. (We do not complicate matters
here by considering possible repair mechanisms that
would have dose-related effects and so necessitate
consideration of I and t separately, as we have not
found depth of necrosis produced by our light
source in vivo to be affected appreciably by varia-
tions in light intensity and duration that keep total
dose fixed (Berenbaum, unpublished). The depth of
necrosis zn is that at which the threshold dose of
singlet oxygen is produced, i.e., the depth at which
attenuation reduces the light dose Do at the surface
(where DO=Iot) to the threshold dose. This may be
calculated from equation (2).
That is, depth of necrosis should be proportional to
the logarithm of light dose, a prediction borne out
by Figure 1. Equation (5) shows that a graph of
depth of necrosis as a function of loge light dose
should be a straight line with slope of v-' and
intercept 0 on the dose axis.
A comparison between the experimental dose-
effect curves of Figure 1 and those calculated from
Table I using equations (4) and (5) is shown in
Figure 3. Calculations were based on the experimen-
tally measured threshold at 630nm, as this would
be least affected by variations in tumour content of
blood, whether oxygenated or not. The photo-
physical parameters (A and S) and depth of necrosis
were perforce measured in two different tumours,
but both are solid, homogeneous, and non-
pigmented, and there was no a priori reason to
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Figure 3 Predicted dose-response curves (solid lines) for light at 630+ 18.6 nm, 514.5 + 18.6 nm and
405+ 18.6 nm. Calculations according to equations (4) and (5), using the relative excitation efficiencies and
attenuation coefficients of Table 1 and the observed threshold of 4.2Jcm-2 at 630 nm. The experimentally
determined curves ofFigure 2 are inserted for comparison (dashed curves as in Figure 2).
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markedly. In fact, as mentioned above, a variety of
normal and neoplastic tissues are found to have
rather similar attenuation coefficients. -Considering
the uncertainties in measuring the optical properties
of tumours and the large variations inherent in
producing and measuring tumour necrosis, we think
that the level of agreement found between calcu-
lated and observed measurements (Figure 3)
suggests that our overall approach is correct,
although much refinement is needed, both
theoretically and experimentally. In particular,
Kubelka-Munk theory has limited validity for the
collimated light we used to treat tumours, and other
analytic methods (Svaasand et al., 1981) may be
more appropriate.
Clinical implications
Figure 1 shows that the dose-effect curves for
tumour necrosis produced by red and green light
respectively intersect at a tissue depth of - 1.25mm,
green light being more efficient at lesser depths.
However, these dose-effect curves do not fully reveal
the potential advantage of green light for thin
tumours with currently available light sources.
Light at 630nm is at present generally produced by
a dye laser pumped by an argon laser, but the
conversion efficiency is at best 20-25%. More than
half the argon output is in the green (514.5nm), the
rest being mainly blue (488nm). Therefore, 2-3
times as much power in the green may be obtained
using the argon laser directly as may be obtained in
the red from the dye laser. Thus, in terms of the
illumination time needed to produce equivalent
depths of necrosis, a more realistic comparison of
the two wavebands would be made by transposing
the dose-effect for green light to the left by a shift
corresponding to a 2-to-3-fold reduction in dose.
The curve for red light and the transposed curve for
green would intersect at a depth of -3.3mm. An
additional effect would be produced by the blue
argon output (488nm), which has about the same
(HpD) excitation efficiency as light at 514.5nm and
nearly the same tissue penetrance. Thus our findings
suggest that, for tumours of up to 3.3mm depth,
and probably more, shorter illumination times
would be entailed by using an argon laser directly
rather than a red-emitting dye laser pumped by it.
This depth encompasses that of tumours more
extensive than carcinoma-in-situ, for example, many
microinvasive carcinomas of the bladder (Farrow &
Utz, 1982).
The argon laser is thus likely to be most useful
where the tumour is thin and a large area requires
illumination, for instance, in widespread carcinoma-
in-situ of the bladder. Ideally, the whole bladder
surface should be illuminated as local treatment is
very likely to be followed by recurrence in the
untreated area (Tsuchiya et al., 1983; Benson et al.,
1983), and delivery of an adequate dose of red light
to the whole mucosa of the distended bladder, 2-
300cm2, with dye lasers now available may be
prohibitively time-consuming. Use of argon laser
with at least 2-3 times as much output at
wavelengths that are more efficient than red in
destroying superficial tumours may be preferable.
Bellnier et al., (1984, 1985) have independently
drawn the same conclusion, after finding that green
and red laser light at equal doses and dose-rates
were equally effective in destroying thin (.2.5mm
deep) tumours.
The question arises as to how far these findings
may be extrapolated to man. Our mice (17-22g)
received 40mgkg-' HpD, equivalent on a surface
area basis to about 3mgkg- in man, a dose within
the clinical range (2.5-5.0mgkg-'). Such
measurements as have been made suggest that 100-
360Jcm 2 of light at 630nm produces 5-10mm
depth of necrosis in human tumours (Dougherty et
al., 1985). Extrapolation of the curve for 630nm in
Figure 1 shows that, in our model, these doses
would produce 6.5-9mm necrosis. Thus, agreement
is surprisingly good.
The log-linear relation between light dose and
depth of necrosis also has important implications. If
the curve for red light in Figure 2 may be
extrapolated, it suggests that it would require about
500Jcm-2 at 630nm to cause necrosis to a depth
of 1 cm, which is feasible with current light sources.
However, producing necrosis to a depth of - 1.5cm
would require - 6000Jcm 2, necessitating either
impracticably long illumination times (a few hours)
or light intensities at which thermal effects would
predominate and selectivity due to photo-
sensitisation would virtually disappear. Therefore
progress in treating large tumours cannot depend
solely on developing light sources of greater power
but also on (a) developing methods for distributing
light more uniformly throughout the tumour and
(b) finding photosensitisers that are excited
efficiently at longer and more penetrating
wavelengths, thus in effect increasing the slope of
the tumour necrosis dose-effect curve.
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